Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease. (31st January 2020)

• Record Type: Journal Article
• Authors: Shivakumar, Oshini; Sattar, Naveed; Wheeler, David C
• Is Part Of: Nephrology dialysis transplantation. Volume 35(2020)Supplement 1
• Page Start: i43
• Page End: i47
• Publication Date: 2020-01-31
• Subjects: cardiovascular disease -- chronic kidney disease -- heart failure -- type 2 diabetes -- SGLT2 inhibitors; Nephrology -- Periodicals; Hemodialysis -- Periodicals; Kidneys -- Transplantation -- Periodicals; Hemodialysis; Kidneys -- Transplantation; Nephrology; Periodicals; 616.61
• DOI: 10.1093/ndt/gfz292
• Languages: English
• ISSNs: 0931-0509

Abstract

Abstract: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events, specifically those related to heart failure in patients with type 2 diabetes. Reductions in major adverse cardiovascular event (MACE) outcomes are also observed, but confined largely to patients who have prior cardiovascular disease. Cardiovascular outcome benefits extend to patients with type 2 diabetes and reduced estimated glomerular filtration (eGFR) rate down to 30 mL/min/1.73 m 2 and to patients with heart failure but without diabetes. Ongoing trials are exploring whether patients with chronic kidney disease (CKD) but without diabetes will gain similar benefits from this class of agents. Although some safety concerns have emerged, it seems likely that SGLT2 inhibitors will be used more widely in CKD patients to reduce their cardiovascular risk.